Perspective Therapeutics, Inc. (CATX) Stock Price

CATXStock

$3.29−13.32%52W

Market Cap$375.56M

P/E—

PEG Ratio—

Div yield—

Beta1.80

CATX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-47.83%

Price vs S&P 500 (4W)8.10%

VGM Score24.64

Book Value / Share (Quarterly)$3.05

P/TBV (Annual)1.22x

Revenue Growth (3Y)-37.09%

Cash Flow / Share (Quarterly)$-0.94

Price vs S&P 500 (YTD)4.04%

Gross Margin (TTM)22.97%

Net Profit Margin (TTM)-17982.69%

EPS (TTM)$-1.40

10-Day Avg Trading Volume1.20M

EPS Excl Extra (TTM)$-1.40

Revenue Growth (5Y)-38.50%

EPS (Annual)$-1.40

ROI (Annual)-49.42%

Gross Margin (Annual)23.10%

Net Profit Margin (5Y Avg)-4127.01%

Cash / Share (Quarterly)$2.38

Revenue Growth QoQ (YoY)-77.78%

ROA (Last FY)-38.63%

Revenue Growth TTM (YoY)-57.99%

EBITD / Share (TTM)$-1.43

ROE (5Y Avg)-32.85%

Operating Margin (TTM)-19419.58%

Cash Flow / Share (Annual)$-1.28

P/B Ratio1.02x

P/B Ratio (Quarterly)1.37x

Net Income / Employee (Annual)$-632,600

EV / Revenue (TTM)487.88x

Net Interest Coverage (TTM)-3.35x

ROA (TTM)-34.64%

EPS Incl Extra (Annual)$-1.40

Current Ratio (Annual)5.17x

Quick Ratio (Quarterly)8.61x

3-Month Avg Trading Volume1.62M

52-Week Price Return-13.32%

Revenue / Employee (TTM)$3,800

Tangible BV / Share (Quarterly)$2.70

P/S Ratio (Annual)400.31x

Asset Turnover (Annual)0.00x

52-Week High$6.16

Operating Margin (5Y Avg)-4448.67%

EPS Excl Extra (Annual)$-1.40

CapEx CAGR (5Y)99.28%

26-Week Price Return-36.58%

Quick Ratio (Annual)5.08x

13-Week Price Return-17.57%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)8.75x

Enterprise Value$301.51M

Revenue / Share Growth (5Y)-34.13%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$5,400

Inventory Turnover (Annual)5.19x

Pretax Margin (Annual)-11813.12%

Cash / Share (Annual)$1.95

3-Month Return Std Dev65.53%

Gross Margin (5Y Avg)42.29%

Net Income / Employee (TTM)$-681,800

ROE (Last FY)-49.81%

Net Interest Coverage (Annual)-2.38x

EPS Basic Excl Extra (Annual)$-1.40

Receivables Turnover (TTM)9.09x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.40

Receivables Turnover (Annual)14.49x

ROI (TTM)-41.59%

P/S Ratio (TTM)572.61x

Pretax Margin (5Y Avg)-4083.08%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$2.25

Price vs S&P 500 (52W)-31.63%

Year-to-Date Return16.00%

5-Day Price Return-0.62%

EPS Normalized (Annual)$-1.40

ROA (5Y Avg)-26.66%

Net Profit Margin (Annual)-11665.27%

Month-to-Date Return9.62%

Cash Flow / Share (TTM)$-0.06

EBITD / Share (Annual)$-1.49

Operating Margin (Annual)-12846.61%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-32.46%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.40

P/TBV (Quarterly)1.55x

P/B Ratio (Annual)0.99x

Inventory Turnover (TTM)4.82x

Pretax Margin (TTM)-18194.17%

Book Value / Share (Annual)$2.79

Price vs S&P 500 (13W)-20.36%

Beta1.80x

Revenue / Share (TTM)$0.01

ROE (TTM)-41.84%

52-Week Low$1.96

vGradeD

gGradeF

mGradeD

vgmGradeD

CATX Earnings Surprise History

Q2 25-0.30est. -0.29

Q3 25-0.35est. -0.32

Q4 25-0.51est. -0.34

Q1 26-0.25est. -0.32

Q2 26-0.22est. -0.27

CATX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
CATXPerspective Therapeutics, Inc.	D	F	D	$3.29
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Perspective Therapeutics, Inc.

Perspective Therapeutics develops targeted radiopharmaceuticals using Lead-212, an alpha-emitting isotope designed to deliver radiation directly to cancer cells. The company's approach aims to improve treatment efficacy while reducing harm to healthy tissue. This technology addresses a significant market need for more selective cancer therapies across multiple tumor types.